Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006074 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1005294 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1006397 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1006453 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1007393 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL330805 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL843600 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL910572 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1007075 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1006646 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12034122-B2 | Electrolytic solution for lithium-ion secondary battery and lithium-ion secondary battery | MURATA MANUFACTURING CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| CN-111492497-B | Charge-transporting varnish and charge-transporting film | 日产化学株式会社 | 2023-05-26 | — | — | CN | disclosed |
| EP-3806220-A1 | ELECTROLYTE FOR LITHIUM-ION SECONDARY CELL, AND LITHIUM-ION SECONDARY CELL | Murata Manufacturing Co., Ltd. (JP) | 2021-04-14 | — | — | EP | disclosed |
| US-20210066756-A1 | ELECTROLYTIC SOLUTION FOR LITHIUM-ION SECONDARY BATTERY AND LITHIUM-ION SECONDARY BATTERY | MURATA MANUFACTURING CO., LTD. (JP) | 2021-03-04 | — | — | US | disclosed |
| CN-112074983-A | Electrolyte for lithium ion secondary battery and lithium ion secondary battery | 株式会社村田制作所 | 2020-12-11 | — | — | CN | disclosed |
| US-20200339825-A1 | CHARGE TRANSPORTING VARNISH AND CHARGE TRANSPORTING THIN FILM | NISSAN CHEMICAL CORPORATION (JP) | 2020-10-29 | — | — | US | disclosed |
| EP-3731291-A1 | CHARGE-TRANSPORTING VARNISH AND CHARGE-TRANSPORTING THIN FILM | Nissan Chemical Corporation (JP) | 2020-10-28 | — | — | EP | disclosed |
| EP-3059235-B1 | TETRAZOLINONE DERIVATIVES AND THEIR USE FOR CONTROLLING PESTS | SUMITOMO CHEMICAL CO (JP) | 2020-10-28 | — | — | EP | disclosed |
| CN-111492497-A | Charge-transporting varnish and charge-transporting film | 日产化学株式会社 | 2020-08-04 | — | — | CN | disclosed |
| CN-110511533-B | Polyether-ether-ketone/tetrafluoroethylene-perfluoroalkoxy vinyl ether copolymer/chopped quartz fiber material, and preparation method and application thereof | 吉林大学 | 2020-08-04 | — | — | CN | disclosed |
| US-20110195355-A1 | CHARGE-TRANSPORTING VARNISHES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-08-11 | — | — | US | disclosed |
| EP-2339659-A1 | CHARGE-TRANSPORTING VARNISHES | Nissan Chemical Industries, Ltd. (JP) | 2011-06-29 | — | — | EP | disclosed |
| EP-2272817-A1 | PAI-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100324314-A1 | PROCESS FOR PRODUCING ESTER COMPOUND | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100230639-A1 | OLIGOANILINE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2143708-A1 | OLIGOANILINE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-01-13 | — | — | EP | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-6238752-B1 | MODIFIED DIAMINE | CHISSO CORPORATION (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-1020442-A1 | NOVEL DIAMINO COMPOUNDS, POLYAMIC ACID, POLYIMIDE, LIQUID-CRYSTAL ALIGNMENT FILM MADE FROM FILM OF THE POLYIMIDE, AND LIQUID-CRYSTAL DISPLAY ELEMENT CONTAINING THE ALIGNMENT FILM | Chisso Corporation (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-6090909-A | Uv-ray-dimerized high molecular compound, liquid crystal aligning film using above high molecular compound and liquid crystal display element using above aligning film | CHISSO CORPORATION (JP) | 2000-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312315-A1 | PAI-1 INHIBITOR | SERPINC1, SERPINE1, SERPINH1 | LMNA 590/4885THRB 1211/4885CA2 2722/4885 |
| US-20100324314-A1 | PROCESS FOR PRODUCING ESTER COMPOUND | ADH1C, ADH5, ADH1A | LMNA 2434/4885THRB 2104/4885CA2 742/4885 |
| US-20100230639-A1 | OLIGOANILINE COMPOUND | OPRD1, NSD1, OCIAD1 | LMNA 3099/4885THRB 997/4885CA2 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.